[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370729-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370729-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","validation-of-guidelines-for-genetic-investigation-of-myeloid-neoplasms-with-germline-predisposition-results-from-a-prospective-cohort-study","Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition - Results from a Prospective Cohort Study","","Multicenter prospective cohort study evaluates the diagnostic yield of Nordic guidelines for germline investigation in myeloid neoplasms and characterizes inherited versus somatic variant spectra. Eighty-five patients meeting Nordic criteria based on suggestive medical or family history and somatic diagnostic findings (CytoMol) underwent enhanced whole-exome sequencing or targeted sequencing. Pathogenic/likely pathogenic germline variants occurred in 35% overall, varying by subgroup. DDX41 variants were most common, with additional unknown significance findings and hereditary cancer syndrome-related variants. Survival analysis explored outcomes after allogeneic stem cell transplantation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/validation-of-guidelines-for-genetic-investigation-of-myeloid-neoplasms-with-germline-predisposition-results-from-a-prospective-cohort-study/370729/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/validation-of-guidelines-for-genetic-investigation-of-myeloid-neoplasms-with-germline-predisposition-results-from-a-prospective-cohort-study/370729.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of the study?","Question",{"text":63,"@type":64},"To assess the diagnostic yield of the Nordic guidelines for germline investigation in myeloid neoplasms and map the spectrum of inherited and somatic variants.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected for genetic investigation?",{"text":68,"@type":64},"Eighty-five patients fulfilling Nordic criteria were recruited based on suggestive medical or family history and relevant somatic diagnostic work-up findings from CytoMol.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key results for germline variant detection?",{"text":72,"@type":64},"Pathogenic or likely pathogenic germline variants were identified in 35% of patients overall, with yield varying across subgroups. DDX41 pathogenic/likely pathogenic variants were the most frequent finding and were mainly observed in the CytoMol subgroup.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370729,1790232403,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study  \nBianca Tesi1,2,3, Anna Robelius4, Berivan Baskin5,6, Vladimir Lazarevic7, Stefan Deneberg3,8, Martin Hglund4, Linda Fogelstrand9,10, Johanna Ungerstedt3,11, Tatjana Pandzic5,6,12,  \nMagnus Tobiasson3,8, Hege Gravdahl Garelius13, Ekaterina Kuchinskaya1,14,15, Fredrik Persson16, Helena ˚Agerstam17,18, Helene Hallbk4, Thoas Fioretos17,18,19, Jessika Nordin5,12, Anna Norberg20, Ann-Charlotte Thuresson5,6, Sren Lehmann3,4, Claes Ladenvall5,12, Gisela Barbany1,2,  \nLovisa Vennstrm13,21, Elisabeth Ejerblad4, Lucia Cavelier1,2, Jrg Cammenga7,22, Martin Jdersten3,8, Eva Hellstrm-Lindberg3,8, and Panagiotis Baliakas5,6,12  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: In a multicenter prospective cohort study, we assessed the diagnostic yield of the Nordic guidelines for germline investigation in myeloid neoplasms and mapped the spectrum of inherited and somatic variants.\u003Cbr>Experimental Design: Eighty-five patients (acute myeloid leukemia, n ¼ 38; myelodysplastic syndromes, n ¼ 26; thrombocytopenia, n ¼ 14; and other, n ¼ 7) fulfilling the Nordic criteria for germline investigation, based on (i) medical history or family history suggestive of a germline condition and (ii) relevant findings from the somatic diagnostic work-up (CytoMol), were recruited. The genetic analysis included enhanced whole-exome sequencing (n ¼ 69) or sequencing of specific variants of interest (n ¼ 16). Results: Pathogenic or likely pathogenic (P/LP) germline variants were identified in 35% of patients (30/85) . The diagnostic yield varied from 6%(1/16) in the family history group to 52%\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (17/33) in the CytoMol group. Germline DDX41 P/LP variants were the most frequent finding (13/30, 43% of all positive cases) almost exclusively found within the CytoMol group (12/13) . Seven variants of unknown significance were also detected ( TERTn ¼ 2 and DDX41, RTEL1, ETV6, PARN, and SAMD9 n ¼ 1) . Five patients carried a P/LP variant in genes associated with another hereditary cancer syndrome (BRCA1 n ¼ 3; PALB2 n ¼ 1; and CHEK2; n ¼ 1) . Survival analysis showed a trend for longer survival among patients with acute myeloid leukemia and confirmed or suspected germline predisposition that underwent allogeneic stem cell transplantation.\u003Cbr>Conclusions: The implementation of the Nordic guidelines ina prospective Swedish cohort results in a high overall diagnostic yield (35%), proving the feasibility and utility of these or similar guidelines in a clinical setting. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nGermline genetic variants are increasingly recognized as contributing factors to the development of myeloid neoplasms (MN)  \n1Department of Clinical Genetics and Genomics, Karolinska University Hospita","cbCaiasLnlP69sQm","https://ap.wps.com/l/cbCaiasLnlP69sQm","pdf",2337767,"English","# Introduction\n## Germline genetic variants in myeloid neoplasms\n# Purpose\n# Experimental Design\n# Results\n## Pathogenic/likely pathogenic germline variant yield\n## DDX41 findings and variant categories\n# Conclusions","[{\"question\":\"What was the main purpose of the study?\",\"answer\":\"To assess the diagnostic yield of the Nordic guidelines for germline investigation in myeloid neoplasms and map the spectrum of inherited and somatic variants.\"},{\"question\":\"How were patients selected for genetic investigation?\",\"answer\":\"Eighty-five patients fulfilling Nordic criteria were recruited based on suggestive medical or family history and relevant somatic diagnostic work-up findings from CytoMol.\"},{\"question\":\"What were the key results for germline variant detection?\",\"answer\":\"Pathogenic or likely pathogenic germline variants were identified in 35% of patients overall, with yield varying across subgroups. DDX41 pathogenic/likely pathogenic variants were the most frequent finding and were mainly observed in the CytoMol subgroup.\"}]","Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition - Results from a Prospective Cohort Study | PDF",1790190094,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06189cfafd8fdd03bef53746dbf18abf.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c05c029b3d081b2f3fac24a21d533679.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d508580592efad1b7879489c338ebd0.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5e9a842023cad29a4f6cbd896ff4dfe.webp",980,1311]